Cell MedX Corp
OTC:CMXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cell MedX Corp
Operating Income
Cell MedX Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cell MedX Corp
OTC:CMXC
|
Operating Income
-$268.4k
|
CAGR 3-Years
27%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
35%
|
CAGR 10-Years
16%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Operating Income
$1.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$5.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$8.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
Cell MedX Corp
Glance View
Cell MedX Corp. is a biotech company, which engages in the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. The company is headquartered in Carson City, Nevada. The company went IPO on 2013-03-11. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its proprietary eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The Company’s eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities (legs) due to strain from exercise or normal household- or work-related activities, as well as for general relaxation.
See Also
What is Cell MedX Corp's Operating Income?
Operating Income
-268.4k
USD
Based on the financial report for May 31, 2024, Cell MedX Corp's Operating Income amounts to -268.4k USD.
What is Cell MedX Corp's Operating Income growth rate?
Operating Income CAGR 5Y
17%
Over the last year, the Operating Income growth was 40%. The average annual Operating Income growth rates for Cell MedX Corp have been 27% over the past three years , 17% over the past five years .
